Rhabdomyolysis (RM) is a potentially life-threatening entity that can lead to acute kidney injury (AKI). Continuous renal replacement therapy (CRRT) alone is known as effective therapy, but the additional use of a hemoadsorber (like CytoSorb®) might increase its efficacy.
Keywords: CytoSorb®; acute kidney injury; myoglobin; renal replacement therapy; rhabdomyolysis.
© 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.